Invention Application
- Patent Title: CMV NEUTRALIZING ANTIGEN BINDING PROTEINS
- Patent Title (中): CMV中和抗原结合蛋白
-
Application No.: US14897374Application Date: 2014-06-09
-
Publication No.: US20160130327A1Publication Date: 2016-05-12
- Inventor: Tong-Ming Fu , Dai Wang , Zhiqiang An
- Applicant: Tong-Ming FU , Dai WANG , Zhiqiang AN
- Applicant Address: US NJ Rahway US TX Auston
- Assignee: Merck Sharp & Dohme Corp.,Board of Regents of the University of Texas System
- Current Assignee: Merck Sharp & Dohme Corp.,Board of Regents of the University of Texas System
- Current Assignee Address: US NJ Rahway US TX Auston
- International Application: PCT/US14/41504 WO 20140609
- Main IPC: C07K16/08
- IPC: C07K16/08
Abstract:
The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). Also encompassed by the invention are antigen binding proteins that have been humanized. The antigen binding proteins of the invention are useful as a therapeutic agent for treating and/or preventing CMV infections in a patient in need thereof.
Public/Granted literature
- US09868777B2 CMV neutralizing antigen binding proteins Public/Granted day:2018-01-16
Information query
